title: Bisphosphonates in cancer therapy.
abstract: Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone destruction. We review here preclinical evidence that bisphosphonates also exert direct antitumour effects and antiangiogenic properties. Furthermore, we describe new insights on how bisphosphonates may act synergistically in combination with antineoplastic drugs or gammadelta T cells to exhibit antitumour activity. These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice.
authors: INSERM, Research Unit U.664, Faculté de Médecine Laennec, Rue Guillaume Paradin, F-69372 Lyon cedex 08, France. verena.stresing@lyon.inserm.fr
authors: Verena
authors: V
authors: Stresing
authors: Florence
authors: F
authors: Daubiné
authors: Ismahène
authors: I
authors: Benzaid
authors: Hannu
authors: H
authors: Mönkkönen
authors: Philippe
authors: P
authors: Clézardin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D001842:Bone and Bones / Q000378:metabolism; D002448:Cell Adhesion; D049109:Cell Proliferation; D004164:Diphosphonates / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D008954:Models, Biological; D008956:Models, Chemical; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004164:Diphosphonates